The Executive Order on Advancing American Kidney Health aimed to slow the progression
of kidney disease, increase access to kidney transplantation, and expand home dialysis.
In order to support the kidney health strategy laid out by the Advancing American
Kidney Health, the National Institutes of Health, the National Institute of Diabetes,
and Digestive, and Kidney Diseases, as well as other funding agencies must dedicate
robust research funding to kidney disease. Currently, federal research investment
for kidney health is less than 1% of Medicare fee-for-service expenditures for Americans
with kidney disease. To address disparities in federal research funding, nephrology
organizations are working together to advocate for increased federal commitment to
kidney disease research. Underfunding of kidney disease research impedes scientific
opportunities and innovation and prevents the collaboration of young investigators
with research faculty that can accelerate the exodus of talent within the nephrology
research workforce. This review provides an overview of the current state of federal
research funding for kidney disease within the United States. In addition, we discuss
ongoing advocacy efforts and programs that aim to increase federal funding for kidney-related
research and accelerate the development of new and better therapies.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Chronic Kidney DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Chronic kidney disease in the United States, 2021.US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA2021
- US renal data system 2020 annual data report: epidemiology of kidney disease in the United States.Am J Kidney Dis. 2021; 77: A7-A8
- Projecting ESRD incidence and prevalence in the United States through 2030.J Am Soc Nephrol. 2019; 30: 127-135
- Originas of the medicare kidney disease entitlement: the Social Security Amendment of 1972.in: Hanna K.E. Biomedical Politics. National Academies Press (U.S.), Washington, DC1991: 176-182
- Kidney-related research in the United States: a position statement from the national kidney foundation and the American Society of Nephrology.Am J Kidney Dis. 2021; 78: 161-167
- H.R. 34-21st century cures act. H.R. 34-114th congress 2015-2016.(Accessed October 15, 2021)
- Symptom burden, depression, and quality of life in chronic and end-stage kidney disease.Clin J Am Soc Nephrol. 2009; 4: 1057-1064
- Research priorities for kidney-related research-an agenda to advance kidney care: a position statement from the national kidney foundation.Am J Kidney Dis. 2021; 79: 141-152
- A path forward for kidney research. Joint ASN-NIDDK Webinar: perspective on the state of NIDDK kidney research and workforce pipeline.https://www.youtube.com/watch?v=avMVRKL_D(Accessed May 7, 2021)Date: February 4, 2021
- A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease.Am J Kidney Dis. 2021; 79: 268-288
- New creatinine- and cystatin C-based equations to estimate GFR without race.N Engl J Med. 2021; 385: 1737-1749
- The national institute of diabetes, digestive and kidney disease. National Kidney Disease Education Program.(Accessed October 15, 2021)
- Chronic Kidney Disease Surveillance System—United states.2021 (Accessed October 19, 2021)
- Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm hg.JAMA. 1967; 202: 1028-1034
- Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.Circulation. 1972; 45: 991-1004
- The national high blood pressure education program: a description of its utility as a generic program model.Health Educ Q. 1984; 11: 225-242
- National heart, lung, and blood institute strategic visioning: setting an agenda together for the NHLBI of 2025.Am J Public Health. 2015; 105: e25-e28
- Decline in cardiovascular mortality: possible causes and implications.Circ Res. 2017; 120: 366-380
- Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017.Lancet. 2020; 395: 709-733
American Association of Medical Colleges. https://Www.aamc.org/data-reports/workforce/interactive-data/active-physicians-who-are-international-medical-graduates-imgs-specialty-2017. Accessed August 20, 2021.
- (Updated 2021.) (Accessed October 21, 2021.)
Article Info
Footnotes
Financial Disclosures: R.M. is employed by the American Society of Nephrology, and H.K. is a consultant for Astra Zeneca and Bayer Pharmaceuticals and a past president of the National Kidney Foundation.
Identification
Copyright
© 2022 by the National Kidney Foundation, Inc. All rights reserved.
